{"id":"W4405319926","doi":"10.1002/jha2.1062","title":"Characteristics of relapsed/refractory diffuse large B‐cell lymphoma patients with durable responses to maveropepimut‐S, pembrolizumab, and cyclophosphamide: Long‐term follow‐up from the SPiReL trial","year":2024,"lang":"en","type":"article","venue":"eJHaem","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Hospital; Baker Hughes (Canada); McGill University Health Centre; Sunnybrook Health Science Centre","funders":"Merck Canada; McGill University Health Centre; Ottawa Hospital Research Institute; London Health Sciences Centre; McGill University","keywords":"Pembrolizumab; Medicine; Regimen; Cyclophosphamide; Internal medicine; Oncology; Immunotherapy; Clinical trial; ELISPOT; Lymphoma; Chemotherapy; Immune system; Immunology; T cell; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001345298,0.0003974917,0.0007304623,0.0002855906,0.0003904068,0.0006364611,0.0003915917,0.0005802028,0.002059032],"category_scores_gemma":[0.0009981485,0.0002121672,0.000640511,0.0003531191,0.0002430516,0.0005265371,0.0003263322,0.000627065,0.0004362425],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003579584,"about_ca_system_score_gemma":0.0003211587,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003985291,"about_ca_topic_score_gemma":0.0007072941,"domain_scores_codex":[0.9995947,0.0001143299,0.00004758802,0.0001104674,0.00006393502,0.00006887675],"domain_scores_gemma":[0.9991122,0.0001778633,0.000267157,0.00007543945,0.00007078984,0.0002965872],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.09308545,0.002483273,0.8496379,0.0002525478,0.001210569,0.0006763349,0.0002341263,0.00125092,0.01034662,0.00008899042,0.002040688,0.03869255],"study_design_scores_gemma":[0.009562756,0.02335194,0.9603235,0.00004003994,0.0006461482,0.001429325,0.0001280518,0.0008495624,0.001090482,0.0001254654,0.002413777,0.00003894961],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99799,0.0005444764,0.00008051081,0.00004468108,0.000009244498,0.00007622618,0.0006891093,0.000006310046,0.0005593861],"genre_scores_gemma":[0.9971513,0.0001023977,0.00008673286,0.00007954745,0.00002246173,0.0001169049,0.002085939,0.000003144821,0.0003515184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002059032,"threshold_uncertainty_score":0.007114649,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01066533123460231,"score_gpt":0.242737969926255,"score_spread":0.2320726386916527,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}